anp enters negotiation on licensing proposal f, page-96

Fluxmaker

This thread is for ATL1103 licensing deal, not ATL1102

You are taking this thread off topic.

There were many threads on ATL1102 early this year. Just do an advanced search.

Here is a summary for the history of ATL1102

ATL1102 (fka ISIS 107248, target is CD49d subunit of VLA-4, licensed from ISIS 12/2001-eligible for royalties and sublicense income): intended for multiple sclerosis, same target as tysabri and running trials the same way: 
6/2008:
successful 8 wk p2a (reduced new active lesions)-
2/2008
partnered w/ Teva, but 3/2010 discontinued development. ISIS rec'd $1.4m sublicense fee 2008 and $2m for manufacturing in 2009. ANP $2m upfront.
9/2010 and 2010
now seeking new partner for MS development. Also considering development of Inhaled formulation for asthma early stage (intend to outlicense, teva had and returned rights for this indication also).
9/2011:
now applied for a patent for indication of "stem cell mobilization" to "enhance value to potential partners"
2012
Licensing term sheet with TJAB. Agreement to be finailised by July 2012